BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Month: March 2022

2 posts
2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025

Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

  • BioTech Health X
  • March 16, 2022
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
1 Shares
0
1
0
0
0
0
0
Inhibikase-Therapeutics-Present-Phase-1-1b-Trial-Results-ADPD-Alzheimers-Parkinsons-Diseases-Conference

Biotech NewsInhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference

  • BioTech Health X
  • March 8, 2022
Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • West Pharmaceutical Services (WST) Could Outperform as Analysts Project $350.77 Price Target
  • Don’t Let the 70.7% YTD Jump Fool You—Axsome Therapeutics (AXSM) Still Faces Massive Downside Risk
  • TG Therapeutics (TGTX) Reports Explosive Q3 Revenue Surge to $161.7M as BRIUMVI Dominates MS Market
  • Abbott Laboratories (ABT) Posts Stunning 21% EPS Growth—Is This the Strongest Healthcare Stock of 2025?
  • Fennec Pharmaceuticals (FENC) Reveals Stunning Japan Trial Data—Hearing Loss Drops from 63% to Just 24%
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • December 2, 2025
    West Pharmaceutical Services (WST) Could Outperform as Analysts Project $350.77 Price Target
    • December 2, 2025
    Don’t Let the 70.7% YTD Jump Fool You—Axsome Therapeutics (AXSM) Still Faces Massive Downside Risk
    • December 2, 2025
    TG Therapeutics (TGTX) Reports Explosive Q3 Revenue Surge to $161.7M as BRIUMVI Dominates MS Market
    • December 2, 2025
    Abbott Laboratories (ABT) Posts Stunning 21% EPS Growth—Is This the Strongest Healthcare Stock of 2025?
    • December 2, 2025
    Fennec Pharmaceuticals (FENC) Reveals Stunning Japan Trial Data—Hearing Loss Drops from 63% to Just 24%
Recent Posts
  • JANUX Therapeutics Just Hit Its Lowest Price Since 2024 — Here’s Why Wall Street Is Still Bullish
    • December 2, 2025
  • Acadia Healthcare (ACHC) Faces 168% Spike in Claims — Investors Ask: Panic or Massive Buying Opportunity?
    • December 2, 2025
  • Astera Labs (ALAB) Surges as New NVLink Fusion Breakthrough Redefines AI Infrastructure
    • December 2, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (599)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top